Related Experiment Video
Updated: Feb 26, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Therapeutic opportunities for CKD-associated osteoporosis in adults with kidney failure imply screening
Thijs Engelen1, Dieter Smout1,2, Michaël R Laurent3,4,5
1Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
Insights
High fracture risk in chronic kidney disease (CKD) patients is common. Comprehensive bone assessments reveal CKD-associated osteoporosis in 73% of kidney failure patients, highlighting unmet treatment needs.
Area of Science:
- Nephrology
- Endocrinology
- Geriatrics
Background:
- Patients with chronic kidney disease (CKD) face significantly elevated fracture risks.
- A European consensus exists for screening osteoporosis in CKD stages G4-5D.
- Data on screening yield and treatment implications in kidney failure patients are limited.
Purpose of the Study:
- To evaluate the effectiveness of comprehensive bone health assessment in identifying CKD-associated osteoporosis in kidney failure patients.
- To determine the prevalence of osteoporosis and related factors in this population.
- To identify therapeutic opportunities for managing bone health in kidney failure.
Main Methods:
- A single-center study invited dialysis patients over 50 or postmenopausal with >1 year life expectancy.
- Assessments included risk factors, calcium intake, mineral metabolism, bone turnover markers, fracture history, bone mineral density (BMD) via DXA, handgrip strength, and physical activity.
- 71 eligible patients underwent comprehensive phenotyping.
Main Results:
- CKD-associated osteoporosis was diagnosed in 73% of patients, based on BMD (65%), fragility fracture history (41%), or vertebral fractures (13%).
- Vitamin D insufficiency (35%) and low calcium intake (29%) were prevalent.
- High bone turnover was suggested in 53% despite normal PTH in most; sarcopenia (65%) and low physical activity (55%) were common. Only 21% received bone-targeting therapy.
Conclusions:
- Comprehensive bone assessment identifies CKD-associated osteoporosis in 70% of kidney failure patients.
- Significant opportunities exist for optimizing mineral metabolism and implementing bone-targeting therapies.
- Findings warrant further investigation and confirmation.
Background:
Fracture risk in patients with chronic kidney disease (CKD) is excessively high. A recent European consensus provides guidance on the comprehensive screening for CKD-associated osteoporosis in patients with CKD stages G4-5D. However, data on the yield and therapeutic implications of this approach in patients with kidney failure is lacking.
Methods:
All prevalent dialysis patients aged >50 years or postmenopausal with life expectancy >1 year at a single center were invited for comprehensive bone health assessment, including the evaluation of risk factors, calcium intake, mineral metabolism parameters, bone turnover markers, fracture history, bone mineral density and vertebral fractures by dual-energy X-ray absorptiometry (DXA), handgrip strength and self-reported physical activity.
Results:
Of 203 patients screened, 121 (mean age 75 years, 55% male) were eligible, of whom 71 underwent comprehensive phenotyping including DXA. CKD-associated osteoporosis was identified in 73% of participants, based on a T-score ≤-2.5 at the hip or lumbar spine (65%), history of fragility fracture (41%) and/or finding of a vertebral fracture (13%). Vitamin D insufficiency (<30 ng/mL) and insufficient calcium intake (<800 mg/day) were observed in 35% and 29%, respectively. Despite bio-intact parathyroid hormone levels exceeding the KDIGO target range in only 17%, bone turnover markers suggested high bone turnover in 53% of patients. Handgrip strength was below sarcopenia threshold in 65%, while physical activity was low in 55% of participants. Only 21% of patients with CKD-associated osteoporosis were treated with bone targeting therapy.
Conclusion:
Comprehensive bone health assessment identified CKD-associated osteoporosis in 7 out of 10 patients with kidney failure and unveiled several therapeutic opportunities ranging from optimization of mineral metabolism to non-pharmacological and pharmacological bone-targeting interventions. The present single-center findings call for reflection and confirmation.
More Related Videos
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Chronic Kidney Disease IV: Nursing Management

